Australian biotech market today 15.04.09
Wednesday, 15 April, 2009
The healthcare index was a bright spot on an otherwise poor day for listed stocks, up 0.32 per cent at 3.30pm today.
Drug delivery company Acrux (ASX:ACR) is up 7c to 70c following yesterday’s ruling that it resume mediation with its US licensee, Vivus, over beginning a Phase III trial of its testosterone spray for women, Luramist.
Alchemia (ASX:ACL) was up 3.5c to 34c while Atcor (ASX:ACG) is up a cent to 21c on today’s news that it has signed two more sales contracts for its SphygmoCor blood pressure systems, bringing total contracts in the past year to US$7.3 million.
Circadian (ASX:CIR) was down a touch, while Cellestis (ASX:CST) lost some of yesterday’s gains, settling at $2.60.
Pharmaxis (ASX:PXS) has regained some of yesterday’s losses and is back over $2.00, while Mesoblast (ASX:MSB) is up a little.
Cochlear (ASX:COH) is down almost a dollar, while CSL (ASX:CSL) is up 40c and ResMed (ASX:RMD) is up 23c.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
